01/15/2026
An update in menopause-related medication labeling
The U.S. Food and Drug Administration announced plans to update labeling for hormone therapy products used in menopause care, following a review of long-standing scientific data.
Labeling plays an important role in how medications are understood and discussed by both clinicians and patients. This update reflects evolving medical guidance and highlights the importance of individualized conversations between patients and their healthcare providers.
Hormone therapy remains prescription-based and is not appropriate for everyone. As with all medications, decisions about use depend on personal health history, timing, and provider guidance.
At Solutions Pharmacy, we support informed care by working closely with prescribing clinicians and helping patients understand their medications as part of a broader healthcare plan.
If you have questions about your prescriptions, we encourage you to speak with your healthcare provider or pharmacist.
This post is for informational purposes only and does not constitute medical advice. Medication decisions should always be made in consultation with a licensed healthcare provider.
The Food and Drug Administration will remove the "black box" warning from hormone replacement therapy (HRT) products for menopause.